drugset / Trial / NCT00375609
Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT)
RandomizedParallel-groupOpen-labelPrevention
Summary
Randomized study of PRT054021 40 mg and 15 mg bid vs. enoxaparin 30 mg q12h for the prophylaxis of venous thromboembolic events after unilateral knee replacement surgery.
Timeline
- Start
- 2006-05
- Primary completion
- 2007-01
- Completion
- 2007-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Betrixaban | Small molecule | 15 mg | Oral |
| Subject | Betrixaban | Small molecule | 40 mg | Oral |
| Subject | Enoxaparin sodium | Other / unclassified | 30 mg | Subcutaneous |